NCT03970447 2026-04-22
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
Clinical Trials
11 trialsNCT05712694 2026-04-20
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group
Phase 3 Recruiting
NCT05813327 2026-04-20
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05616624 2026-04-15
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT06085729 2026-04-02
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07389278 2026-02-05
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
NCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
NCT03449901 2025-12-11
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed